Investigational drug · Phase 3
LP352
Also called: bexicaserin
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
6
Any phase or sponsor naming "LP352"
First trial start
2022
Nov 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LP352", any sponsor or status.
Conditions studied
As listed on its trial records.
- Developmental and Epileptic Encephalopathy
- Dravet Syndrome
- Lennox-Gastaut Syndrome
Approved drugs for the same conditions: Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "LP352" as an intervention, largest first.
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Pivotal-lookingActive, not recruiting
Longboard PharmaceuticalsIndustry
NCT06719141 · 367 participants · Start Nov 11, 2024 · Primary completion Oct 31, 2026
Drug: LP352; Placebo · For: Developmental and Epileptic Encephalopathy
Sites: Little Rock, Arkansas; Los Angeles, California; Palo Alto, California · 116 sites in all
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Pivotal-lookingEnrolling by invitation
Longboard PharmaceuticalsIndustry
NCT06908226 · 324 participants (planned) · Start Feb 12, 2025 · Primary completion Nov 11, 2027
Drug: LP352 · For: Developmental and Epileptic Encephalopathy
Sites: Little Rock, Arkansas; Los Angeles, California; Palo Alto, California · 88 sites in all
- A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Pivotal-lookingActive, not recruiting
Longboard PharmaceuticalsIndustry
NCT06660394 · 108 participants · Start Sep 25, 2024 · Primary completion Dec 31, 2026
Drug: LP352; Placebo · For: Dravet Syndrome
Sites: Little Rock, Arkansas; Los Angeles, California; Palo Alto, California · 105 sites in all
Longboard PharmaceuticalsIndustry
NCT05364021 · 52 participants · Start Mar 3, 2022 · Primary completion Nov 16, 2023
Drug: LP352; Placebo · For: Developmental and Epileptic Encephalopathy; Dravet Syndrome; Lennox Gastaut Syndrome
Sites: Tucson, Arizona; Little Rock, Arkansas; Downey, California · 34 sites in all
Longboard PharmaceuticalsIndustry
NCT05626634 · 41 participants · Start Nov 8, 2022 · Primary completion Dec 20, 2024
Drug: LP352, bexicaserin · For: Developmental and Epileptic Encephalopathy; Dravet Syndrome; Lennox-Gastaut Syndrome
Sites: Little Rock, Arkansas; Downey, California; San Francisco, California · 28 sites in all
Longboard PharmaceuticalsIndustry
NCT06149663
Drug: LP352 · For: Dravet Syndrome; Lennox Gastaut Syndrome; Developmental and Epileptic Encephalopathies
Sites: Downey, California; Los Angeles, California; San Francisco, California · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.
Martins WA · Curr Issues Mol Biol 2026
- Development and Validation of an LC-MS/MS Method for the Quantitative Estimation of Bexicaserin in Human Cerebrospinal Fluid.
Kallem RR, Chan R, Neal K, et al. · Biomed Chromatogr 2026
- An LC-MS/MS Method for the Quantitation of Metabolites M9, M12, and M20 of Bexicaserin in Human Cerebrospinal Fluid.
Kallem RR, Chan R, Yeager M, et al. · Biomed Chromatogr 2026
- Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).
Dlugos DJ, Scheffer IE, French JA, et al. · Epilepsia 2026
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First-in-Human Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Phase 1 Study.
Chan R, Orevillo C, O'Connell G, et al. · Clin Pharmacol Drug Dev 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.